<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INVIRASE - saquinavir mesylate tablet, film coated </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<h1>INVIRASE<span class="Sup">® </span><br>(saquinavir mesylate) <br>CAPSULES and TABLETS</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Product identification in this document includes: INVIRASE in reference to saquinavir mesylate; saquinavir soft gel capsules in reference to saquinavir 200 mg soft gel capsule formulation<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>, and saquinavir in reference to the active base.</span></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>The term "saquinavir soft gel capsules" used in this label refers to the drug product formerly marketed as "Fortovase" (saquinavir 200 mg soft gel capsule formulation).  This formulation has been withdrawn from the market.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">INVIRASE brand of saquinavir mesylate is an inhibitor of the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) protease. INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free base). Each capsule also contains the inactive ingredients lactose, microcrystalline cellulose, povidone K30, sodium starch glycolate, talc, and magnesium stearate. Each capsule shell contains gelatin and water with the following dye systems: red iron oxide, yellow iron oxide, black iron oxide, FD&amp;C Blue #2, and titanium dioxide.</p>
<p>INVIRASE is also available as a light orange to greyish- or brownish-orange, oval cylindrical, biconvex film-coated tablet for oral administration in a 500-mg strength (as saquinavir free base). Each tablet also contains the inactive ingredients lactose, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. Each film coat contains hypromellose, titanium dioxide, talc, iron oxide yellow, iron oxide red, and triacetin.</p>
<p> The chemical name for saquinavir mesylate is N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide methanesulfonate with a molecular formula C<span class="Sub">38</span>H<span class="Sub">50</span>N<span class="Sub">6</span>O<span class="Sub">5</span>•CH<span class="Sub">4</span>O<span class="Sub">3</span>S and a molecular weight of 766.96. The molecular weight of the free base is 670.86. Saquinavir mesylate has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8b53129-06ab-4143-b9b7-7675e49a52ef&amp;name=invirase-01.jpg"></div>
<p>Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="MICROBIOLOGY"></a><a name="section-3"></a><p></p>
<h1>MICROBIOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Saquinavir is an inhibitor of HIV protease. HIV protease is an enzyme required for the proteolytic cleavage of viral polyprotein precursors into individual functional proteins found in infectious HIV. Saquinavir is a peptide-like substrate analogue that binds to the protease active site and inhibits the activity of the enzyme. Saquinavir inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature noninfectious virus particles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Antiviral Activity</h2>
<p class="First">In vitro antiviral activity of saquinavir was assessed in lymphoblastoid and monocytic cell lines and in peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Saquinavir inhibited HIV activity in both acutely and chronically infected cells. IC<span class="Sub">50</span> and IC<span class="Sub">90</span> values (50% and 90% inhibitory concentrations) were in the range of 1 to 30 nM and 5 to 80 nM, respectively. In the presence of 40% human serum, the mean IC<span class="Sub">50</span> of saquinavir against laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV-1 RF in MT4 cells was 37.7± 5 nM representing a 4-fold increase in the IC<span class="Sub">50</span> value. In cell culture, saquinavir demonstrated additive to synergistic effects against HIV-1 in combination with reverse transcriptase inhibitors (didanosine, lamivudine, nevirapine, stavudine and zidovudine) without enhanced cytotoxicity. Saquinavir in combination with the protease inhibitors amprenavir, atazanavir, or lopinavir resulted in synergistic antiviral activity. Saquinavir displayed antiviral activity in vitro against HIV-1 clades A-H (IC<span class="Sub">50</span> ranged from 0.9 to 2.5 nM). The IC<span class="Sub">50  </span>and IC<span class="Sub">90</span> values of saquinavir against HIV-2 isolates in vitro ranged from 0.25 nM to 14.6 nM and 4.65 nM to 28.6 nM, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First">HIV-1 mutants with reduced susceptibility to saquinavir have been selected during in vitro passage. Genotypic analyses of these isolates showed several substitutions in the HIV protease gene. Only the G48V and L90M substitutions were associated with reduced susceptibility to saquinavir, and conferred an increase in the IC<span class="Sub">50</span> value of 8- and 3-fold, respectively.</p>
<p>HIV-1 isolates with reduced susceptibility (≥4-fold increase in the IC<span class="Sub">50</span> value) to saquinavir emerged in some patients treated with INVIRASE. Genotypic analysis of these isolates identified resistance conferring primary mutations in the protease gene G48V and L90M, and secondary mutations L10I/R/V, I54V/L, A71V/T, G73S, V77I, V82A and I84V that contributed additional resistance to saquinavir. Forty-one isolates from 37 patients failing therapy with INVIRASE had a median decrease in susceptibility to saquinavir of 4.3-fold.</p>
<p>The degree of reduction in in vitro susceptibility to saquinavir of clinical isolates bearing substitutions G48V and L90M depends on the number of secondary mutations present. In general, higher levels of resistance are associated with greater number of mutations only in association with either or both of the primary mutations G48V and L90M. No data are currently available to address the development of resistance in patients receiving saquinavir/ritonavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Cross-resistance</h2>
<p class="First">Among protease inhibitors, variable cross-resistance has been observed. In one clinical study, 22 HIV-1 isolates with reduced susceptibility (&gt;4-fold increase in the IC<span class="Sub">50</span> value) to saquinavir following therapy with INVIRASE were evaluated for cross-resistance to amprenavir, indinavir, nelfinavir and ritonavir. Six of the 22 isolates (27%) remained susceptible to all 4 protease inhibitors, 12 of the 22 isolates (55%) retained susceptibility to at least one of the PIs and 4 out of the 22 isolates (18%) displayed broad cross-resistance to all PIs. Sixteen (73%) and 11 (50%) of the 22 isolates remained susceptible (&lt;4-fold) to amprenavir and indinavir, respectively. Four of 16 (25%) and nine of 21 (43%) with available data remained susceptible to nelfinavir and ritonavir, respectively.</p>
<p>After treatment failure with amprenavir, cross-resistance to saquinavir was evaluated. HIV-1 isolates from 22/22 patients failing treatment with amprenavir and containing one or more mutations M46L/I, I50V, I54L, V32I, I47V, and I84V were susceptible to saquinavir.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-4.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetic properties of INVIRASE have been evaluated in healthy volunteers (n=351) and HIV-infected patients (n=270) after single- and multiple-oral doses of 25, 75, 200, and 600 mg three times daily and in healthy volunteers after intravenous doses of 6, 12, 36 or 72 mg (n=21). The pharmacokinetics of INVIRASE/ritonavir 1000/100 mg twice daily have also been evaluated in HIV-infected patients.</p>
<p>Similar bioavailability was demonstrated when INVIRASE 500 mg film-coated tablet (2 × 500 mg) and INVIRASE 200 mg capsule (5 × 200 mg) were administered with low-dose ritonavir (100 mg) under fed conditions. The ratio of mean exposures (90% confidence intervals) of tablets vs capsules were 1.10 (1.04-1.16) for AUC<span class="Sub">0-∞</span> and 1.19 (1.14-1.25) for C<span class="Sub">max</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Absorption and Bioavailability in Adults</h2>
<p class="First">Absolute bioavailability of saquinavir administered as INVIRASE averaged 4% (CV 73%, range: 1% to 9%) in 8 healthy volunteers who received a single 600-mg dose (3 × 200 mg) of saquinavir mesylate following a high-fat breakfast (48 g protein, 60 g carbohydrate, 57 g fat; 1006 kcal). The low bioavailability is thought to be due to a combination of incomplete absorption and extensive first-pass metabolism. </p>
<p>INVIRASE in combination with ritonavir at a dose of 1000/100 mg twice daily provides saquinavir systemic exposures over a 24-hour period that are similar to those achieved with saquinavir soft gel capsules (FORTOVASE) with ritonavir 1000/100 mg twice daily and greater than that achieved with saquinavir soft gel capsules 1200 mg three times daily (see <span class="Bold"><a href="#table1">Table 1</a></span>). The 1200 mg three times daily regimen for FORTOVASE was an approved regimen for which efficacy of saquinavir was demonstrated. Thus, the exposure resulting from this FORTOVASE regimen forms the lower bound for efficacy for all subsequent saquinavir dosing regimens.<span class="Sup">1</span></p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1 Pharmacokinetic Parameters of Saquinavir at Steady-State After Administration of Different Regimens in HIV-Infected Patients</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosing Regimen</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">AUC<span class="Sub">τ</span><br>(ng∙h/mL)</th>
<th class="Rrule" align="center">AUC<span class="Sub">24h</span><br>(ng∙h/mL)</th>
<th class="Rrule" align="center">C<span class="Sub">min</span><br>(ng/mL)</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">τ is the dosing interval (ie, 8h if three times daily and 12h if twice daily)</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">INVIRASE 600 mg tid (arithmetic mean, %CV)</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">866 (62)</td>
<td class="Rrule" align="center">2598</td>
<td class="Rrule" align="center">79</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir soft gel capsules (FORTOVASE) 1200 mg tid (arithmetic mean)</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">7249</td>
<td class="Rrule" align="center">21747</td>
<td class="Rrule" align="center">216</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">INVIRASE 1000 mg bid + ritonavir 100 mg bid (geometric mean and 95% CI)</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">14607<br> (10218-20882)</td>
<td class="Rrule" align="center">29214</td>
<td class="Rrule" align="center">371<br> (245-561)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Saquinavir soft gel capsules 1000 mg bid + ritonavir 100 mg bid (geometric mean and 95% CI)</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">19085<br> (13943-26124)</td>
<td class="Rrule" align="center">38170</td>
<td class="Rrule" align="center">433<br> (301-622)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2>Food Effect</h2>
<p class="First">No food effect data are available for INVIRASE in combination with ritonavir.</p>
<p>The mean 24-hour AUC after a single 600-mg oral dose (6 × 100 mg) in healthy volunteers (n=6) was increased from 24 ng∙h/mL (CV 33%), under fasting conditions, to 161 ng∙h/mL (CV 35%) when INVIRASE was given following a high-fat breakfast (48 g protein, 60 g carbohydrate, 57 g fat; 1006 kcal). Saquinavir 24-hour AUC and C<span class="Sub">max</span> (n=6) following the administration of a higher calorie meal (943 kcal, 54 g fat) were on average 2 times higher than after a lower calorie, lower fat meal (355 kcal, 8 g fat). The effect of food has been shown to persist for up to 2 hours.</p>
<p>Saquinavir exposure was similar when saquinavir soft gel capsules plus ritonavir (1000-mg/100-mg twice daily) were administered following a high-fat (45 g fat) or moderate-fat (20 g fat) breakfast.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Distribution in Adults</h2>
<p class="First">The mean steady-state volume of distribution following intravenous administration of a 12-mg dose of saquinavir (n=8) was 700 L (CV 39%), suggesting saquinavir partitions into tissues. Saquinavir was approximately 98% bound to plasma proteins over a concentration range of 15 to 700 ng/mL. In 2 patients receiving saquinavir mesylate 600 mg three times daily, cerebrospinal fluid concentrations were negligible when compared to concentrations from matching plasma samples.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>Metabolism and Elimination in Adults</h2>
<p class="First">In vitro studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90% of the hepatic metabolism. Based on in vitro studies, saquinavir is rapidly metabolized to a range of mono- and di-hydroxylated inactive compounds. In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study using 600 mg <span class="Sup">14</span>C-saquinavir mesylate (n=8), 88% and 1% of the orally administered radioactivity was recovered in feces and urine, respectively, within 5 days of dosing. In an additional 4 subjects administered 10.5 mg <span class="Sup">14</span>C-saquinavir intravenously, 81% and 3% of the intravenously administered radioactivity was recovered in feces and urine, respectively, within 5 days of dosing. In <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance studies, 13% of circulating radioactivity in plasma was attributed to unchanged drug after oral administration and the remainder attributed to saquinavir metabolites. Following intravenous administration, 66% of circulating radioactivity was attributed to unchanged drug and the remainder attributed to saquinavir metabolites, suggesting that saquinavir undergoes extensive first-pass metabolism.</p>
<p>Systemic clearance of saquinavir was rapid, 1.14 L/h/kg (CV 12%) after intravenous doses of 6, 36, and 72 mg. The mean residence time of saquinavir was 7 hours (n=8).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2>Special Populations</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2>Hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Saquinavir pharmacokinetics in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has not been investigated (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>). Only 1% of saquinavir is excreted in the urine, so the impact of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on saquinavir elimination should be minimal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.8"></a><p></p>
<h2>Gender, Race, and Age</h2>
<p class="First">A gender difference was observed, with females showing higher saquinavir exposure than males (mean AUC 56% higher, mean C<span class="Sub">max </span>26% higher), in the relative bioavailability study comparing INVIRASE 500 mg film-coated tablets to the INVIRASE 200 mg capsules in combination with ritonavir. There was no evidence that age and body weight explained the gender difference in this study. A clinically significant difference in safety and efficacy between men and women has not been reported with the approved dosage regimen (saquinavir 1000-mg/ritonavir 100-mg twice daily).</p>
<p>The effect of race on the pharmacokinetics of saquinavir has not been investigated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.9"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">The pharmacokinetics of saquinavir have not been sufficiently investigated in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.10"></a><p></p>
<h2>Geriatric Patients</h2>
<p class="First">The pharmacokinetics of saquinavir have not been sufficiently investigated in patients &gt;65 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.11"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">(see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>)</p>
<p>Drug interaction studies have been completed with INVIRASE and the saquinavir soft gel capsule formulation. Because ritonavir is coadministered, prescribers should refer to the prescribing information for ritonavir regarding drug interactions associated with this drug.</p>
<p><span class="Bold"><a href="#table2">Table 2 </a></span>summarizes the effect of saquinavir soft gel capsules on the geometric mean AUC and C<span class="Sub">max</span> of coadministered drugs. <span class="Bold"><a href="#table3">Table 3 </a></span>summarizes the effect of coadministered drugs on the geometric mean AUC and C<span class="Sub">max</span> of saquinavir.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2 Effect of Saquinavir on the Pharmacokinetics of Coadministered Drugs</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Saquinavir soft gel capsules or saquinavir soft gel capsules/ ritonavir<br>Dose</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Rrule" align="center" colspan="2">% Change for Coadministered Drug</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">AUC (95% CI)</th>
<th class="Rrule" align="center">C<span class="Sub">max</span> (95% CI)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">↑      Denotes an average increase in exposure by the percentage indicated.<br>↓      Denotes an average decrease in exposure by the percentage indicated.<br>↔    Denotes no statistically significant change in exposure was observed.<br>P      Patient<br>V     Healthy Volunteers<br>M    Methadone-dependent, HIV negative patients<br>NA  Not Available</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>90% Confidence Interval</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Clarithromycin 500 mg bid × 7 days</td>
<td class="Rrule" align="left">1200 mg tid × 7 days</td>
<td class="Rrule" align="center">12V</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Clarithromycin</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↑45% (17-81%)</td>
<td class="Rrule" align="center">↑39% (10-76%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  14-OH clarithromycin metabolite</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">↓24% (5-40%)</td>
<td class="Rrule" align="center">↓34% (14-50%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Enfuvirtide 90 mg SC q12h (bid) for 7 days</td>
<td class="Rrule Toprule" align="left">1000/100 mg bid</td>
<td class="Botrule Rrule Toprule" align="center">12P</td>
<td class="Rrule Toprule" align="center">↔</td>
<td class="Botrule Rrule Toprule" align="center">↔</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Rifabutin 300 mg qd</td>
<td class="Rrule Toprule" align="left">1200 mg tid</td>
<td class="Botrule Rrule" align="center">14P</td>
<td class="Rrule Toprule" align="center">↑44%</td>
<td class="Botrule Rrule" align="center">↑45%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Sildenafil 100-mg single dose</td>
<td class="Rrule Toprule" align="left">1200 mg tid × 8 days</td>
<td class="Rrule" align="center">27V</td>
<td class="Rrule Toprule" align="center">↑210% (150-300%)</td>
<td class="Rrule" align="center">↑140% (80-230%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Efavirenz 600 mg qd</td>
<td class="Rrule" align="left">1200 mg tid</td>
<td class="Rrule" align="center">13V</td>
<td class="Rrule" align="center">↓12%</td>
<td class="Rrule" align="center">↓13%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center"><span class="Bold">Invirase or Invirase/ritonavir Dose</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Digoxin 0.5 mg single dose</td>
<td class="Rrule" align="left">1000/100 mg bid × 16 days</td>
<td class="Rrule" align="center">16V</td>
<td class="Rrule" align="center">↑49% (32-69%)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">↑27% (5-54%)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">R-Methadone 60-120 mg qd</td>
<td class="Rrule" align="left">1000/100 mg bid × 14 days</td>
<td class="Rrule" align="center">12M</td>
<td class="Rrule" align="center">↓19% (9-29%)<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketoconazole 200 mg/day</td>
<td class="Rrule" align="left">1000/100 mg bid</td>
<td class="Rrule" align="center">12V</td>
<td class="Rrule" align="center">↑168% (146-193%)<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">↑45% (32-59%)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Midazolam 7.5 mg oral single dose</td>
<td class="Rrule" align="left">1000/100 mg bid</td>
<td class="Rrule" align="center">16V</td>
<td class="Rrule" align="center">↑1144% (975-1339%)<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">↑327% (264 -402%)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="100%">
<caption><span>Table 3 Effect of Coadministered Drugs on Saquinavir Pharmacokinetics</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Saquinavir soft gel capsules Dose</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Rrule" align="center" colspan="2">% Change for Saquinavir</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">AUC (95% CI)</th>
<th class="Rrule" align="center">C<span class="Sub">max</span> (95% CI)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">↑      Denotes an average increase in exposure by the percentage indicated.<br>↓      Denotes an average decrease in exposure by the percentage indicated.<br>↔    Mean change &lt;10%<br>P      Patient<br>V     Healthy Volunteers</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Compared to standard saquinavir soft gel capsules 1200 mg tid regimen (n=33).</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Did not reach statistical significance.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>Compared to standard INVIRASE 600 mg tid regimen (n=114).</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd>90% Confidence Interval</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left">Clarithromycin 500 mg bid × 7 days</td>
<td class="Rrule Toprule" align="left">1200 mg tid × 7 days</td>
<td class="Rrule Toprule" align="center">12V</td>
<td class="Rrule Toprule" align="center">↑177% (108-269%)</td>
<td class="Rrule Toprule" align="center">↑187% (105-300%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Efavirenz 600 mg qd</td>
<td class="Rrule Toprule" align="left">1200 mg tid</td>
<td class="Botrule Rrule Toprule" align="center">13V</td>
<td class="Rrule Toprule" align="center">↓62%</td>
<td class="Botrule Rrule Toprule" align="center">↓50%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Indinavir 800 mg q8h × 2 days</td>
<td class="Rrule Toprule" align="left">1200 mg single dose</td>
<td class="Botrule Rrule" align="center">6V</td>
<td class="Rrule Toprule" align="center">↑364% (190-644%)</td>
<td class="Botrule Rrule" align="center">↑299% (138-568%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Rifabutin 300 mg qd</td>
<td class="Rrule Toprule" align="left">1200 mg tid</td>
<td class="Rrule" align="center">14P</td>
<td class="Rrule Toprule" align="center">↓47%</td>
<td class="Rrule" align="center">↓39%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir 400 mg bid × 14 days</td>
<td class="Rrule" align="left">400 mg bid × 14 days<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">8V</td>
<td class="Rrule" align="center">↑121% (7-359%)</td>
<td class="Rrule" align="center">↑64%<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Lopinavir/ritonavir <br> Evidence from several clinical trials indicates that saquinavir concentrations achieved with saquinavir 1000 mg + lopinavir/ritonavir 400/100 mg BID are similar to those achieved following saquinavir/ritonavir 1000/100 mg BID.</td></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Invirase or Invirase/ritonavir Dose</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Rrule" align="center" colspan="2">% Change for Saquinavir</th>
</tr>
<tr>
<th class="Rrule" align="center">AUC (95% CI)</th>
<th class="Rrule" align="center">C<span class="Sub">max</span> (95% CI)</th>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Atazanavir 300 mg qd</td>
<td class="Botrule Rrule" align="left">1600/100 mg qd</td>
<td class="Botrule Rrule" align="center">18P</td>
<td class="Rrule Toprule" align="center">↑60% <br> (16-122%)</td>
<td class="Rrule Toprule" align="center">↑42%<br> (10-84%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Fosamprenavir 700 mg bid</td>
<td class="Botrule Rrule" align="left">1000 mg bid/100 mg bid</td>
<td class="Botrule Rrule" align="center">18P</td>
<td class="Rrule Toprule" align="center">↓15%<br> (-33% to 9%)</td>
<td class="Rrule Toprule" align="center">↔</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir 100 mg bid</td>
<td class="Rrule" align="left">1000 mg bid<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">24P</td>
<td class="Rrule Toprule" align="center">↑1124%</td>
<td class="Rrule Toprule" align="center">↑1325%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tenofovir 300 mg qd</td>
<td class="Rrule" align="left">1000 mg bid/100 mg bid</td>
<td class="Rrule" align="center">18P</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">↔</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tipranavir 500 mg + ritonavir 200 mg bid</td>
<td class="Rrule" align="left">600 mg bid/100 mg bid</td>
<td class="Rrule" align="center">20P</td>
<td class="Rrule" align="center">↓76% <br> (68-81%)<a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a>
</td>
<td class="Rrule" align="center">↓70%<br> (60-77%)<a href="#footnote-6" class="Sup">§</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Omeprazole 40 mg qd × 5 days</td>
<td class="Rrule" align="left">1000/100 mg bid × 15 days</td>
<td class="Rrule" align="center">19V</td>
<td class="Rrule" align="center">↑82%<br> (37-234%)<a href="#footnote-6" class="Sup">§</a>
</td>
<td class="Rrule" align="center">↑ 75%<br> (31-234%)<a href="#footnote-6" class="Sup">§</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Ketoconazole 200 mg/day</td>
<td class="Rrule" align="left">1000 mg bid/100 mg bid</td>
<td class="Rrule" align="center">20V</td>
<td class="Rrule" align="center">↔<a href="#footnote-6" class="Sup">§</a>
</td>
<td class="Rrule" align="center">↔</td>
</tr>
</tbody>
</table>
<p>For information regarding clinical recommendations, see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>, <span class="Bold"><a href="#table5">Table 5</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 study (see <span class="Bold"><a href="#table6">Table 6</a></span>) and pharmacokinetic data (see <span class="Bold"><a href="#table1">Table 1</a></span>). The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Description of Clinical Studies</h2>
<p class="First">In a randomized, double-blind clinical study (NV14256) in zidovudine-experienced, HIV-infected patients, INVIRASE in combination with zalcitabine was shown to be superior to either INVIRASE or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to AIDS-defining events or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Furthermore, in a randomized study (ACTG229/NV14255), patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> with history of prolonged zidovudine treatment and who were given INVIRASE 600 mg (three times daily) + zidovudine + zalcitabine experienced greater increases in CD4 cell counts as compared to those who received INVIRASE + zidovudine or zalcitabine + zidovudine. It should be noted that HIV treatment regimens that were used in these initial clinical studies of INVIRASE are no longer considered standard of care.</p>
<p>Saquinavir gel capsule 1000 mg twice daily coadministered with ritonavir 100 mg twice daily was studied in a heterogeneous population of 148 HIV-infected patients (MaxCmin 1 study). At baseline 42 were treatment naïve and 106 were treatment experienced (of which 52 had an HIV RNA level &lt;400 copies/mL at baseline). Results showed that 91/148 (61%) subjects achieved and/or sustained an HIV RNA level &lt;400 copies/mL at the completion of 48 weeks.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">INVIRASE is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to saquinavir, saquinavir mesylate, or any of its ingredients including ritonavir.</p>
<p>INVIRASE/ritonavir should not be administered concurrently with rifampin, terfenadine, cisapride, astemizole, pimozide, triazolam, midazolam or ergot derivatives. Inhibition of CYP3A4 by saquinavir and ritonavir could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions, such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> or prolonged sedation (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>).</p>
<p>INVIRASE/ritonavir should not be given together with rifampin, due to the risk of severe hepatocellular toxicity if the three drugs are given together (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a>)</span>.</p>
<p>INVIRASE when administered with ritonavir is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>INVIRASE/ritonavir should not be administered concurrently with drugs listed in <span class="Bold"><a href="#table4">Table 4</a></span>.</p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4 Drugs That Are Contraindicated With INVIRASE/Ritonavir</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Drug Class</th>
<th class="Rrule" align="left">Drugs Within Class That Are Contraindicated With INVIRASE</th>
<th class="Rrule" align="left">Clinical Comment</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Antiarrhythmics</td>
<td class="Rrule" align="left">Amiodarone, bepridil, flecainide, propafenone, quinidine</td>
<td class="Rrule" align="left">Potential for serious and/or threatening reactions.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ergot Derivatives</td>
<td class="Rrule" align="left">Dihydroergotamine, ergonovine, ergotamine, methylergonovine</td>
<td class="Rrule" align="left">Potential for serious and life threatening reactions such as ergot toxicity characterized by peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimycobacterial Agents</td>
<td class="Rrule" align="left">Rifampin</td>
<td class="Rrule" align="left">Rifampin should not be administered in patients taking ritonavir-boosted INVIRASE part of an ART regimen due to the risk of severe hepatocellular toxicity.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">GI Motility Agent</td>
<td class="Rrule" align="left">Cisapride</td>
<td class="Rrule" align="left">Potential for serious and/or life threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Neuroleptics</td>
<td class="Rrule" align="left">Pimozide</td>
<td class="Rrule" align="left">Potential for serious and/or life threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sedative/Hypnotics</td>
<td class="Rrule" align="left">Triazolam, orally administered midazolam</td>
<td class="Rrule" align="left">Potential for serious and/or life threatening reactions such as prolonged or increased sedation or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.<br> <br>Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam and orally administered midazolam with INVIRASE/ritonavir may cause large increases in the concentration of these benzodiazepines. </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">HMG-CoA Reductase Inhibitors</td>
<td class="Rrule" align="left">Lovastatin, Simvastatin</td>
<td class="Rrule" align="left">Potential for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">INVIRASE must be used in combination with ritonavir.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Interaction with HMG-CoA Reductase Inhibitors</h2>
<p class="First">INVIRASE should not be used with lovastatin or simvastatin (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span>. Caution should be exercised if HIV protease inhibitors, including INVIRASE, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (eg, atorvastatin). Since increased concentrations of statins can, in rare cases, cause severe adverse events such as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, this risk may be increased when HIV protease inhibitors, including saquinavir, are used in combination with these drugs (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Interaction with St. John's Wort (hypericum perforatum)</h2>
<p class="First">Concomitant use of INVIRASE and St. John's wort (hypericum perforatum) or products containing St. John's wort is not recommended. Coadministration of protease inhibitors, including INVIRASE, with St. John's wort is expected to substantially decrease protease-inhibitor concentrations and may result in sub-optimal levels of INVIRASE and lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Interaction with Digoxin</h2>
<p class="First">Caution should be exercised when INVIRASE and digoxin are coadministered; serum concentration of digoxin should be monitored and the dose of digoxin may need to be reduced (see<span class="Bold"><a href="#PreDI"> PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Interaction with Fluticasone</h2>
<p class="First">A drug interaction study in healthy subjects has shown that ritonavir significantly increases plasma fluticasone propionate exposures, resulting in significantly decreased serum cortisol concentrations. Concomitant use of INVIRASE with ritonavir and fluticasone propionate is expected to produce the same effects. Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate. Therefore, coadministration of fluticasone propionate and INVIRASE/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First">New onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, exacerbation of preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported during postmarketing surveillance in HIV-infected patients receiving protease-inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for the treatment of these events. In some cases <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> has occurred. In those patients who discontinued protease-inhibitor therapy, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease-inhibitor therapy and these events has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">If a serious or severe toxicity occurs during treatment with INVIRASE, INVIRASE should be interrupted until the etiology of the event is identified or the toxicity resolves. At that time, resumption of treatment with full-dose INVIRASE may be considered. For antiretroviral agents used in combination with INVIRASE, physicians should refer to the complete product information for these drugs for dose adjustment recommendations and for information regarding drug-associated adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Hepatic Effects</h2>
<p class="First">The use of INVIRASE (in combination with ritonavir) by patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied. In the absence of such studies, caution should be exercised, as increases in saquinavir levels and/or increases in liver enzymes may occur. In patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C, cirrhosis, <span class="product-label-link" type="condition" conceptid="435243" conceptname="Alcohol dependence">chronic alcoholism</span> and/or other underlying liver abnormalities there have been reports of worsening liver disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Renal clearance is only a minor elimination pathway; the principal route of metabolism and excretion for saquinavir is by the liver. Therefore, no initial dose adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have not been studied, and caution should be exercised when prescribing saquinavir in this population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></h2>
<p class="First">There have been reports of spontaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> and B treated with protease inhibitors. In some patients additional factor VIII was required. In the majority of reported cases treatment with protease inhibitors was continued or restarted. A causal relationship between protease inhibitor therapy and these episodes has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">Elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and/or triglyceride levels have been observed in some patients taking saquinavir in combination with ritonavir. Marked elevation in triglyceride levels is a risk factor for development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and triglyceride levels should be monitored prior to initiating combination dosing regimen of INVIRASE with ritonavir, and at periodic intervals while on such therapy. In these patients, lipid disorders should be managed as clinically appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4143342" conceptname="Lactose intolerance">Lactose Intolerance</span></h2>
<p class="First">Each capsule contains lactose (anhydrous) 63.3 mg. This quantity should not induce specific symptoms of intolerance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreFD"></a><a name="section-8.7"></a><p></p>
<h2>Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving antiretroviral therapy. A causal relationship between protease-inhibitor therapy and these events has not been established and the long-term consequences are currently unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including INVIRASE. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9"></a><p></p>
<h2>Resistance/Cross-resistance</h2>
<p class="First">Varying degrees of cross-resistance among protease inhibitors have been observed. Continued administration of INVIRASE therapy following loss of viral suppression may increase the likelihood of cross-resistance to other protease inhibitors (see <span class="Bold"><a href="#MICROBIOLOGY">MICROBIOLOGY</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.10"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">A statement to patients and health care providers is included on the product's bottle label: <span class="Bold">ALERT: Find out about medicines that should NOT be taken with INVIRASE.</span></p>
<p>INVIRASE may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, nonprescription medication, or herbal products, particularly St. John's wort.</p>
<p>Patients should be informed that INVIRASE is not a cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and that they may continue to acquire illnesses associated with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should be advised that<span class="Bold"> INVIRASE must be used in combination with ritonavir, which significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels. </span></p>
<p>Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving protease inhibitors and that the cause and long-term health effects of these conditions are not known at this time.</p>
<p>Patients should be told that the long-term effects of INVIRASE are unknown at this time. They should be informed that INVIRASE therapy has not been shown to reduce the risk of transmitting HIV to others through sexual contact or blood contamination.</p>
<p>Patients should be advised that INVIRASE administered with ritonavir should be taken within 2 hours after a full meal (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span>). When INVIRASE is taken without food, concentrations of saquinavir in the blood are substantially reduced and may result in no antiviral activity. Patients should be advised of the importance of taking their medication every day, as prescribed, to achieve maximum benefit. Patients should not alter the dose or discontinue therapy without consulting their physician. If a dose is missed, patients should take the next dose as soon as possible. However, the patient should not double the next dose.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.11"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Clinical chemistry tests, viral load, and CD4 count should be performed prior to initiating INVIRASE therapy and at appropriate intervals thereafter. Elevated nonfasting triglyceride levels have been observed in patients in saquinavir trials. Triglyceride levels should be periodically monitored during therapy. For comprehensive information concerning laboratory test alterations associated with use of other antiretroviral therapies, physicians should refer to the complete product information for these drugs.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="PreDI"></a><a name="section-8.12"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Bold">Drug interaction studies have been completed with INVIRASE and saquinavir soft gel capsules. Observations from drug interaction studies with saquinavir soft gel capsules may not be predictive for INVIRASE/ritonavir.</span> Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.</p>
<p>The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism. Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp). Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir. Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp.</p>
<p>Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed in <span class="Bold"><a href="#table4">Table 4</a></span> under <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.</p>
<p>Drug interactions that have been established based on drug interaction studies are listed with the pharmacokinetic results in <span class="Bold"><a href="#table2">Table 2</a></span>, which summarizes the effect of saquinavir, administered as saquinavir soft gel capsules or INVIRASE, on the geometric mean AUC and C<span class="Sub">max</span> of coadministered drugs and <span class="Bold"><a href="#table3">Table 3</a></span>, which summarizes the effect of coadministered drugs on the geometric mean AUC and C<span class="Sub">max</span> of saquinavir. Clinical dose recommendations can be found in <span class="Bold"><a href="#table5">Table 5</a></span>. The magnitude of the interactions may be different when INVIRASE is given with ritonavir (see <span class="Bold"><a href="#CP">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>When coadministering INVIRASE/ritonavir with any agent having a narrow therapeutic margin, such as anticoagulants, anticonvulsants, and antiarrhythmics, special attention is warranted. With some agents, the metabolism may be induced, resulting in decreased concentrations. Examples and clinical dose recommendations can be found in <span class="Bold"><a href="#table5">Table 5</a></span>.</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5 Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or on Predicted Interaction with INVIRASE/ritonavir</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Concomitant Drug Class:<br>Drug Name</th>
<th class="Rrule" align="center">Effect on  Concentration of Saquinavir or Concomitant Drug</th>
<th class="Rrule" align="center">Clinical Comment</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>INVIRASE/ritonavir interaction has not been evaluated.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>See <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY: Pharmacokinetics</a></span>, <span class="Bold"><a href="#table2">Table 2</a></span> and <span class="Bold"><a href="#table3">Table 3</a></span> for magnitude of interactions.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">HIV-Antiviral Agents</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span><br>Delavirdine<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ Saquinavir<br> <br> Effect on delavirdine is not well established</td>
<td class="Rrule" align="left">Appropriate doses of the combination with respect to safety and efficacy have not been established.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span><br>Efavirenz<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>,<br>nevirapine<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ Saquinavir<br>↔ Efavirenz</td>
<td class="Rrule" align="left">Appropriate doses of the combination of efavirenz or nevirapine and INVIRASE/ritonavir (1000/100 mg bid) with respect to safety and efficacy have not been established. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HIV protease inhibitor:</span><br>Atazanavir<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">
<span class="Bold">INVIRASE/ritonavir</span><br>↑ Saquinavir<br>↑ Ritonavir<br>↔ Atazanavir</td>
<td class="Rrule" align="left">Appropriate dosing recommendations for this combination, with respect to efficacy and safety, have not been established. When 1600 mg INVIRASE/100 mg ritonavir and 300 mg atazanavir were coadministered, plasma concentrations of saquinavir and ritonavir were increased.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HIV protease inhibitor:</span><br>Indinavir<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ Saquinavir<br> <br> Effect on indinavir is not well established</td>
<td class="Rrule" align="left">Appropriate doses of the combination of indinavir and INVIRASE/ritonavir with respect to safety and efficacy have not been established.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HIV protease inhibitor:</span><br> Lopinavir/ritonavir<a href="#footnote-8" class="Sup">†</a> (coformulated capsule)</td>
<td class="Rrule" align="left">↔ Saquinavir<br>↔ Lopinavir<br>↓ Ritonavir</td>
<td class="Rrule" align="left">Evidence from several clinical trials indicates that saquinavir concentrations achieved with the saquinavir and lopinavir/ritonavir combination are similar to those achieved following saquinavir/ritonavir 1000/100 mg. The recommended dose for this combination is saquinavir 1000 mg plus lopinavir/ritonavir 400/100 mg bid.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HIV protease inhibitor:</span><br>Tipranavir/ritonavir<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">↓ Saquinavir</td>
<td class="Rrule" align="left">Combining saquinavir with tipranavir/ritonavir is not recommended.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HIV fusion inhibitor:</span><br>Enfuvirtide<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">Saquinavir soft gel capsules/ritonavir<br>↔ enfuvirtide</td>
<td class="Rrule" align="left">No clinically significant interaction was noted from a study in 12 HIV patients who received enfuvirtide concomitantly with saquinavir soft gel capsules/ritonavir 1000/100 mg bid. No dose adjustments are required.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Other Agents</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antiarrhythmics:</span><br>Lidocaine (systemic)<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ Antiarrhythmics</td>
<td class="Rrule" align="left">Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics given with INVIRASE/ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Anticoagulant:</span><br>Warfarin<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ Warfarin</td>
<td class="Rrule" align="left">Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Anticonvulsants:</span><br>Carbamazepine<a href="#footnote-7" class="Sup">*</a>, phenobarbital<a href="#footnote-7" class="Sup">*</a>, phenytoin<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ Saquinavir<br> <br>Effect on carbamazepine, phenobarbital, and phenytoin is not well established</td>
<td class="Rrule" align="left">Use with caution, saquinavir may be less effective due to decreased saquinavir plasma concentrations in patients taking these agents concomitantly.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Anti-infective:</span><br>Clarithromycin<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">↑ Saquinavir<br>↑ Clarithromycin<br>
</td>
<td class="Rrule" align="left">Appropriate doses of the combination of clarithromycin and INVIRASE/ritonavir with respect to safety and efficacy have not been established.<br> <br> Due to the known effect of ritonavir on clarithromycin concentrations, the following dose adjustments are recommended: <br> For patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the following dosage adjustments should be considered:<br> <ul>
<li>For patients with CL<span class="Sub">CR</span> 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.</li>
<li>For patients with CL<span class="Sub">CR</span> &lt;30 mL/min the dose of clarithromycin should be decreased by 75%.</li>
</ul>No dose adjustment for patients with normal renal function is necessary.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antifungal:</span><br>Ketoconazole<a href="#footnote-8" class="Sup">†</a>, itraconazole<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↔ Saquinavir<br>↔ Ritonavir<br>↑ Ketoconazole</td>
<td class="Rrule" align="left">Appropriate doses of the combination of ketoconazole or itraconazole and INVIRASE/ritonavir with respect to safety and efficacy have not been established. When INVIRASE/ritonavir and ketoconazole are coadministered, plasma concentration of ketoconazole was increased (see <span class="Bold"><a href="#table2">Table 2</a></span>). Hence, doses of ketoconazole &gt; 200 mg/day are not recommended. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antimycobacterial:</span><br>Rifabutin<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">↓ Saquinavir<br>↑ Rifabutin</td>
<td class="Rrule" align="left">Appropriate doses of the combination of rifabutin and INVIRASE/ritonavir with respect to safety and efficacy have not been established.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Benzodiazepines<a href="#footnote-7" class="Sup">*</a>:</span><br>Alprazolam, clorazepate, diazepam, flurazepam</td>
<td class="Rrule" align="left">↑ Benzodiazepines</td>
<td class="Rrule" align="left">Clinical significance is unknown; however, a decrease in benzodiazepine dose may be needed.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Benzodiazepine</span><a href="#footnote-7" class="Sup">*</a><span class="Bold">:</span><br> Intravenously administered Midazolam</td>
<td class="Rrule" align="left">↑ Midazolam</td>
<td class="Rrule" align="left">Midazolam is extensively metabolized by CYP3A4. Increases in the concentration of midazolam are expected to be significantly higher with oral than parenteral administration. Therefore, INVIRASE should not be given with orally administered midazolam [see <a href="#CONTRAINDICATIONS">Contraindications (4)</a>]. If INVIRASE is coadministered with parenteral midazolam, close clinical monitoring for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or prolonged sedation should be exercised and dosage adjustment should be considered. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Calcium channel blockers</span><a href="#footnote-7" class="Sup">*</a><span class="Bold">:</span><br> Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine</td>
<td class="Rrule" align="left">↑ Calcium channel blockers</td>
<td class="Rrule" align="left">Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Corticosteroid:</span><br> Dexamethasone<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ Saquinavir</td>
<td class="Rrule" align="left">Use with caution, saquinavir may be less effective due to decreased saquinavir plasma concentrations in patients taking these agents concomitantly.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Digitalis Glycosides: </span><br>Digoxin<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">↑ Digoxin<br> <br> Increases in serum digoxin concentration were greater in female subjects as compared to male subjects when digoxin was coadministered with INVIRASE/ritonavir.</td>
<td class="Rrule" align="left">Concomitant use of INVIRASE/ritonavir with digoxin results in a significant increase in serum concentrations of digoxin. Caution should be exercised when INVIRASE/ritonavir and digoxin are coadministered; serum digoxin concentrations should be monitored and the dose of digoxin may need to be reduced when coadministered with INVIRASE/ritonavir (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">
<span class="Bold">Inhaled/nasal steroid:</span><br> Fluticasone<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">
<span class="Bold">INVIRASE/ritonavir</span><br>↑ Fluticasone</td>
<td class="Rrule" align="left">Concomitant use of fluticasone propionate and INVIRASE/ritonavir may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations. Coadministration of fluticasone propionate and INVIRASE/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HMG-CoA reductase inhibitors</span><a href="#footnote-7" class="Sup">*</a><span class="Bold">:</span><br>Atorvastatin, rosuvastatin</td>
<td class="Rrule" align="left">↑ Atorvastatin<br>↑ Rosuvastatin  </td>
<td class="Rrule" align="left">Use lowest possible dose of atorvastatin or rosuvastatin  with careful monitoring, or consider other HMG-CoA reductase inhibitors such as fluvastatin in combination with Invirase/ritonavir (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Immunosuppressants</span><a href="#footnote-7" class="Sup">*</a><span class="Bold">:</span><br> Cyclosporine, tacrolimus, rapamycin</td>
<td class="Rrule" align="left">↑ Immunosuppressants </td>
<td class="Rrule" align="left">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Narcotic analgesic:</span><br> Methadone<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">↓ Methadone</td>
<td class="Rrule" align="left">Dosage of methadone may need to be increased when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Oral contraceptives:</span><br> Ethinyl estradiol<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ Ethinyl estradiol</td>
<td class="Rrule" align="left">Alternative or additional contraceptive measures should be used when estrogen-based oral contraceptives and INVIRASE/ritonavir are coadministered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">PDE5 inhibitors</span><span class="Bold">(phosphodiesterase type 5 inhibitors):</span><br> Sildenafil<a href="#footnote-8" class="Sup">†</a>, vardenafil<a href="#footnote-7" class="Sup">*</a>, tadalafil<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ Sildenafil<br>↔ Saquinavir<br> <br> ↑ Vardenafil<br> ↑ Tadalafil</td>
<td class="Rrule" align="left">Use sildenafil with caution at reduced doses of 25 mg every 48 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br> <br> Use vardenafil with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br> <br> Use tadalafil with caution at reduced doses of no more than 10 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antidepressant:</span><br>Trazodone <a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ Trazodone</td>
<td class="Rrule" align="left">Concomitant use of trazodone and INVIRASE/ritonavir may increase plasma concentration of trazodone. Adverse events of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as INVIRASE/ritonavir, the combination should be used with caution and lower dose of trazodone should be considered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Tricyclic antidepressants</span><a href="#footnote-7" class="Sup">*</a><span class="Bold">: </span>Amitriptyline, imipramine</td>
<td class="Rrule" align="left">↑ Tricyclics</td>
<td class="Rrule" align="left">Therapeutic concentration monitoring is recommended for tricyclic antidepressants when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Proton pump inhibitors: </span>Omeprazole<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="left">↑ Saquinavir</td>
<td class="Rrule" align="left">When INVIRASE/ritonavir is co-administered with omeprazole, saquinavir concentrations are increased significantly. If omeprazole or another proton pump inhibitor is taken concomitantly with INVIRASE/ritonavir, caution is advised and monitoring for potential saquinavir toxicities is recommended, particularly  <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>,  increased triglycerides, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Herbal Products:</span><br> St. John's wort<a href="#footnote-7" class="Sup">*</a> (hypericum perforatum)</td>
<td class="Rrule" align="left">↓ Saquinavir</td>
<td class="Rrule" align="left">Coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Garlic Capsules<a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ Saquinavir</td>
<td class="Rrule" align="left">Coadministration of garlic capsules and saquinavir is not recommended due to the potential for garlic capsules to induce the metabolism of saquinavir which may result in sub-therapeutic saquinavir concentrations. </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.13"></a><p></p>
<h2>Drugs That Are Mainly Metabolized by CYP3A4</h2>
<p class="First">Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (e.g., calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may result in elevated plasma concentrations of these drugs when coadministered with saquinavir; therefore, these combinations should be used with caution. Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.14"></a><p></p>
<h2>Inducers of CYP3A4</h2>
<p class="First">Coadministration with compounds that are potent inducers of CYP3A4 (e.g., phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.15"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.16"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">Carcinogenicity studies found no indication of carcinogenic activity in rats and mice administered saquinavir for approximately 2 years. Because of limited bioavailability of saquinavir in animals, the plasma exposures (AUC values) in the respective species were approximately 29% (using rat) and 65% (using mouse) of those obtained in humans at the recommended clinical dose boosted with ritonavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.17"></a><p></p>
<h2>Mutagenesis</h2>
<p class="First">Mutagenicity and genotoxicity studies, with and without metabolic activation where appropriate, have shown that saquinavir has no mutagenic activity in vitro in either bacterial (Ames test) or mammalian cells (Chinese hamster lung V79/HPRT test). Saquinavir does not induce chromosomal damage in vivo in the mouse micronucleus assay or in vitro in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and does not induce primary DNA damage in vitro in the unscheduled DNA synthesis test.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.18"></a><p></p>
<h2>Impairment of Fertility</h2>
<p class="First">No adverse effects were reported in fertility and reproductive performance study conducted in rats. Because of limited bioavailability of saquinavir in animals, the maximal plasma exposures achieved in rats were approximately 26% of those obtained in humans at the recommended clinical dose boosted with ritonavir.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.19"></a><p></p>
<h2>Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.20"></a><p></p>
<h2>Teratogenic Effects: Category B</h2>
<p class="First">Reproduction studies conducted with saquinavir have shown no embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in both rats and rabbits. Because of limited bioavailability of saquinavir in animals and/or dosing limitations, the plasma exposures (AUC values) in the respective species were approximately 29% (using rat) and 21% (using rabbit) of those obtained in humans at the recommended clinical dose boosted with ritonavir. Clinical experience in pregnant women is limited. Saquinavir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.21"></a><p></p>
<h2>Antiretroviral Pregnancy Registry</h2>
<p class="First">To monitor maternal-fetal outcomes of pregnant women exposed to antiretroviral medications, including INVIRASE, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.22"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV</span>-<span class="Bold">infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV.</span> It is not known whether saquinavir is excreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breast-feed if they are receiving antiretroviral medications, including INVIRASE.</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.23"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of INVIRASE in HIV-infected pediatric patients younger than 16 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.24"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of INVIRASE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be taken when dosing INVIRASE in elderly patients due to the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Concomitant Therapy with Ritonavir Adverse Reactions</h2>
<p class="First">In combination with ritonavir the recommended dose of INVIRASE is 1000 mg two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents. <span class="Bold"><a href="#table6">Table 6</a></span> lists grade 2, 3 and 4 adverse events that occurred in ≥2% of patients receiving saquinavir soft gel capsules with ritonavir (1000/100 mg bid).</p>
<a name="table6"></a><table width="80%">
<caption><span>Table 6 Grade 2, 3 and 4 Adverse Events (All Causality<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>) Reported in ≥2% of Adult Patients in the MaxCmin 1 Study of saquinavir soft gel capsules in Combination with Ritonavir 1000/100 mg bid</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Adverse Events</th>
<th class="Rrule" align="center">Saquinavir soft gel capsules 1000 mg plus Ritonavir 100 mg bid (48 weeks)<br>N=148<br>n (%=n/N)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Includes events with unknown relationship to study drug</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span></td>
<td class="Rrule" align="center">4 (2.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span> </td>
<td class="Rrule" align="center">8 (5.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">16 (10.8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">11 (7.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">12 (8.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">9 (6.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">3 (2.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">9 (6.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">5 (3.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Rrule" align="center">3 (2.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorders</span></span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">8 (5.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Rrule" align="center">4 (2.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Rrule" align="center">4 (2.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">4 (2.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Dermatological Disorders</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">5 (3.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">5 (3.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">Dry lips</span>/skin</td>
<td class="Rrule" align="center">3 (2.0)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span></td>
<td class="Rrule" align="center">3 (2.0)</td>
</tr>
</tbody>
</table>
<p>Limited experience is available from three studies investigating the pharmacokinetics of the INVIRASE 500 mg film-coated tablet compared to the INVIRASE 200 mg capsule in healthy volunteers (n=140). In two of these studies saquinavir was boosted with ritonavir; in the other study, saquinavir was administered as single drug. The INVIRASE tablet and the capsule formulations were similarly tolerated. The most common adverse events were <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> (such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Similar bioavailability was demonstrated and no clinically significant differences in saquinavir exposures were seen. Thus, similar safety profiles are expected between the two INVIRASE formulations.</p>
<p>In a study investigating the drug-drug interaction of rifampin 600 mg/day daily and INVIRASE 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted INVIRASE) involving 28 healthy volunteers, 11 of 17 healthy volunteers (65%) exposed concomitantly to rifampin and ritonavir-boosted INVIRASE developed severe hepatocellular toxicity which presented as increased hepatic transaminases. In some subjects, transaminases increased up to &gt;20-fold the upper limit of normal and were associated with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, including <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Following discontinuation of all three drugs, clinical symptoms abated and the increased hepatic transaminases normalized (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Additional Adverse Reactions Reported with Saquinavir</h2>
<p class="First">Additionally, adverse experiences of any intensity, at least remotely related to saquinavir, that were reported from clinical trials using INVIRASE or saquinavir soft gel capsules with or without ritonavir, are listed below by body system:</p>
<p>Body as a Whole: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, mucosa damage, parasites external, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">retrosternal pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span> syndrome, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness generalized</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, redistribution/accumulation of body fat (see <span class="Bold"><a href="#preFD">PRECAUTIONS: Fat Redistribution</a></span>) </p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">heart murmur</span>, heart valve disorder, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">peripheral vasoconstriction</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vein distended</span> </p>
<p>Endocrine/Metabolic: appetite decrease, appetite disturbance, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span> </p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4260546" conceptname="Ulcerative stomatitis">buccal mucosa ulceration</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic abdominal</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> with grade 4 LFT, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">feces bloodstained</span>, <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">feces discolored</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">gastralgia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="437915" conceptname="Gastrointestinal mucositis">gastrointestinal inflammation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">hemorrhage rectum</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4279681" conceptname="Hepatosplenomegaly">hepatosplenomegaly</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="197484" conceptname="Diarrhea of presumed infectious origin">infectious diarrhea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, liver enzyme disorder, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pain pelvic</span>, <span class="product-label-link" type="condition" conceptid="4025947" conceptname="Pain associated with defecation">painful defecation</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, parotid disorder, <span class="product-label-link" type="condition" conceptid="192680" conceptname="Portal hypertension">portal hypertension</span>, right and left upper quadrant <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, salivary glands disorder, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4048265" conceptname="Increased frequency of defecation">frequent bowel movements</span></p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> dermal, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">microhemorrhages</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="24660" conceptname="Acute tonsillitis">angina tonsillaris</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">infection bacterial</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">infection mycotic</span>, <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">infection staphylococcal</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span></p>
<p>Investigations: ALT increase, AST increase, GGT increase, increased alkaline phosphatase, increased creatine phosphokinase, increased gamma GT, isolated increase in transaminase, raised amylase, raised LDH, TSH increase  </p>
<p>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps leg</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> muscle, creatine phosphokinase increased, <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, tissue changes, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> </p>
<p>Neoplasms benign, malignant and unspecified: <span class="product-label-link" type="condition" conceptid="4073533" conceptname="Acute myeloid leukemia">acute myeloblastic leukemia</span> </p>
<p>Neurological: <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, extremity <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, heart rate disorder, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>, light-headed feeling, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">mouth dry</span>, myelopolyradiculoneuritis, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> face, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> facial, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">poliomyelitis</span>, prickly sensation, <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> </p>
<p>Psychological: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety attack</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">dreaming excessive</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, intellectual ability reduced, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4186941" conceptname="Sexual desire disorder">libido disorder</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> effect, psychic disorder, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span></p>
<p>Reproductive System: <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, prostate enlarged, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span></p>
<p>Respiratory: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, pulmonary disease, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></p>
<p>Skin and Appendages: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, bullous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> and <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span>, <span class="product-label-link" type="condition" conceptid="381581" conceptname="Chalazion">chalazion</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">dermatitis seborrheic</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, hair changes, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomatosis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, pigment changes skin, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular, severe cutaneous reaction associated with increased liver function tests, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">skin nodule</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">verruca</span>, <span class="product-label-link" type="condition" conceptid="4198562" conceptname="Xeroderma">xeroderma</span> </p>
<p>Special Senses: <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, ear pressure, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing decreased</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span></p>
<p>Urinary System: micturition disorder, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">Additional adverse events that have been observed during the postmarketing period are similar to those seen in clinical trials with INVIRASE and saquinavir soft gel capsules alone or in combination with ritonavir.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is limited experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with saquinavir. </p>
<p>No acute toxicities or sequelae were noted in 1 patient who ingested 8 grams of INVIRASE as a single dose. The patient was treated with induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> within 2 to 4 hours after ingestion. A second patient ingested 2.4 grams of INVIRASE in combination with 600 mg of ritonavir and experienced <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the throat that lasted for 6 hours and then resolved. In an exploratory Phase II study of oral dosing with INVIRASE at 7200 mg/day (1200 mg q4h), there were no serious toxicities reported through the first 25 weeks of treatment.</p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with saquinavir should consist of general supportive measures including monitoring of vital signs and ECG and observations of the patient's clinical status. Since saquinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">INVIRASE must be used in combination with ritonavir, because it significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Adults (Over the Age of 16 Years)</h2>
<ul>
<li>INVIRASE 1000-mg twice daily (5 × 200-mg capsules or 2 × 500-mg tablets) in combination with ritonavir 100-mg twice daily.</li>
<li>Ritonavir should be taken at the same time as INVIRASE.</li>
<li>INVIRASE and ritonavir should be taken within 2 hours after a meal.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Concomitant Therapy:  INVIRASE with Lopinavir/Ritonavir</h2>
<p class="First">When administered with lopinavir/ritonavir 400/100 mg twice daily, the appropriate dose of INVIRASE is 1000 mg twice daily (with no additional ritonavir).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Monitoring of Patients</h2>
<p class="First">Clinical chemistry tests, viral load, and CD4 count should be performed prior to initiating INVIRASE therapy and at appropriate intervals thereafter. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2>Dose Adjustment for Combination Therapy with INVIRASE</h2>
<p class="First">For serious toxicities that may be associated with INVIRASE, the drug should be interrupted. INVIRASE at doses less than 1000 mg with 100 mg ritonavir twice daily are not recommended since lower doses have not shown antiviral activity. For recipients of combination therapy with INVIRASE and ritonavir, dose adjustments may be necessary. These adjustments should be based on the known toxicity profile of the individual agent and the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between saquinavir and the coadministered drug (see <span class="Bold"><a href="#PreDI">PRECAUTIONS: Drug Interactions</a></span>). Physicians should refer to the complete product information for these drugs for comprehensive dose adjustment recommendations and drug-associated adverse reactions of nucleoside analogues.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HS"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">INVIRASE 200-mg capsules are light brown and green opaque capsules with ROCHE and 0245 imprinted on the capsule .</p>
<p>INVIRASE 500-mg film-coated tablets are light orange to greyish- or brownish-orange, oval cylindrical, biconvex tablets with ROCHE and SQV 500 imprinted on the tablet face.</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0674-1</td>
<td align="center">500 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">light orange to greyish-or brownish-orange</td>
<td align="center">0004-0244</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2></h2>
<p class="First">The capsules and tablets should be stored at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] in tightly closed bottles.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Capsules Manufactured by:<br>F. Hoffmann-La Roche Ltd., Basel, Switzerland</p>
<p>Tablets Manufactured by:<br>Roche Farma, S.A., Leganes, Spain</p>
<p>Distributed by:<br><span class="Bold">Roche Laboratories Inc.</span><br>340 Kingsland Street<br>Nutley, New Jersey 07110-1199</p>
<p>Copyright © 1998-2010 by Roche Laboratories Inc. All rights reserved.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-14"></a><p></p>
<h1>Patient Information About INVIRASE (in-ver-ase)</h1>
<p class="First"><span class="Bold">INVIRASE<span class="Sup">®</span><br>(saquinavir mesylate)<br>CAPSULES and TABLETS<br>Generic Name: Saquinavir mesylate (sa-KWIN-a-veer mes-il-late)</span></p>
<p><span class="Bold">ALERT: Find out about medicines that should NOT be taken with INVIRASE.</span></p>
<p>Please read this product information carefully before you start taking INVIRASE and each time you renew your prescription. There may be new information. Reading this information can help you take this medicine correctly. However, it is not a substitute for your doctor's advice about the safety and benefits of INVIRASE. You should talk to your doctor about INVIRASE as part of your long-term treatment plan for HIV before you start taking your medication and ask any questions you may have at regular checkups. Remember, you should remain under a doctor's care when using INVIRASE and should not change or stop your therapy without talking to your doctor first.</p>
<p><span class="Bold">What is INVIRASE?</span></p>
<p>INVIRASE belongs to a class of anti-HIV medicines called protease (PRO-tee-ase) inhibitors. INVIRASE Capsules and Tablets in combination with other anti-HIV drugs are used for the treatment of HIV, the virus that causes AIDS (<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span>).</p>
<p><span class="Bold">How does INVIRASE work?</span></p>
<p>INVIRASE fights HIV as it grows inside cells by blocking an enzyme (protease) that HIV needs to reproduce.</p>
<p><span class="Bold">Who should not take INVIRASE?</span></p>
<p>Anyone who has had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g. trouble breathing or severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>) to INVIRASE or any of the ingredients in the capsule or tablet should not take it. The use of INVIRASE in patients under 16 years of age, over 65 years of age, or patients with severe liver problems has not been fully investigated.</p>
<p><span class="Bold">How should INVIRASE/NORVIR<span class="Sup">®</span> (ritonavir) be taken?</span></p>
<ul>
<li>The recommended dosage of INVIRASE in combination with NORVIR (ritonavir) is INVIRASE 5 capsules or 2 tablets twice a day taken with 1 capsule of NORVIR twice a day. Your doctor may change the dose of other medications you may be taking for other illnesses.</li>
<li>INVIRASE must be taken along with NORVIR (ritonavir).</li>
<li>INVIRASE must be taken with meals or up to 2 hours after a meal—but it is easiest to remember if you take it with your meals. When INVIRASE is taken without food, the amount of INVIRASE in the blood is lower and may not fight HIV as well.</li>
<li>When taking INVIRASE and other anti-HIV medicines, it is very important to follow the directions exactly and take your medication every day. If you skip doses—or take less than the prescribed dose—the medicine will not work as well, and your disease could get worse.<dl>
<dt>–</dt>
<dd>If you miss a dose, you should take the next dose as soon as possible. However, do not double the dose.</dd>
</dl>
</li>
</ul>
<p><span class="Bold">What results have been seen with INVIRASE?</span></p>
<p>INVIRASE with NORVIR has been shown to reduce the amount of virus in the blood ("viral load") and increase CD4 (T) cells when taken with other HIV therapy. </p>
<p><span class="Bold">What are the side effects of INVIRASE?</span></p>
<p>People treated with INVIRASE in combination with NORVIR may have side effects. The majority of these have been described as mild. In clinical studies of patients who received saquinavir in combination with NORVIR and other HIV drugs, the side effects seen most often were: body fat change (5.4%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (10.8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (7.4%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8.1%), <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> (6.1%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> (6.1%), and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (5.4%).</p>
<p><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (new onset or worsening) and increased blood sugar levels have been reported with the use of protease inhibitors. In addition, increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> has also been associated with these drugs.</p>
<p>When INVIRASE is taken with NORVIR, some patients may experience large increases in triglyceride and lipid levels. The long-term chance of getting complications such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> due to increases in triglyceride and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels caused by protease inhibitors is not known at this time.</p>
<p>Changes in body fat have been seen in some patients taking anti-HIV medications. These changes may include increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), breasts, and around the trunk. Loss of fat from the legs and arms may also happen. The cause and long-term health effects of these conditions are not known at this time.</p>
<p>These are not the only side effects that can occur with INVIRASE. Your doctor can discuss with you a more complete list of side effects and laboratory abnormalities that may accompany this medication.</p>
<p>If any side effects or unusual symptoms do occur, contact your doctor immediately. Do not stop or decrease your dose on your own. Lowering the dose may make INVIRASE less effective in fighting HIV.</p>
<p><span class="Bold">Are there other medications that I should not take with INVIRASE/NORVIR (ritonavir)?</span></p>
<p>There are some drugs that should not be taken with INVIRASE/NORVIR. Before starting therapy with INVIRASE/NORVIR, be sure to tell your doctor all of the medicines—prescription medications, as well as over-the-counter drugs and nutritional supplements—that you are now taking or plan to take. </p>
<table width="100%">
<caption><span></span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<thead>
<tr class="First Toprule"><th class="Botrule" align="center" colspan="2"><span class="Underline">Medicines you should not take with INVIRASE/NORVIR</span></th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Drug Class</th>
<th class="Rrule" align="left">Drugs Within Class Not to Be Taken with INVIRASE/NORVIR (ritonavir)</th>
</tr>
</thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>No longer sold in the US.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Antiarrhythmics</td>
<td class="Rrule" align="left">PACERONE<span class="Sup">®</span> (amiodarone), TAMBOCOR<span class="Sup">®</span> (flecainide), RHYTHMOL<span class="Sup">®</span> (propafenone), bepridil, quinidine</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimigraines</td>
<td class="Rrule" align="left">Ergot medications (e.g. WIGRAINE<span class="Sup">®</span> and CAFERGOT<span class="Sup">®</span>)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">GI motility agents</td>
<td class="Rrule" align="left">PROPULSID<span class="Sup">®</span> (cisapride)<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sedatives, hypnotics</td>
<td class="Rrule" align="left">VERSED<span class="Sup">®</span> (orally administered midazolam), Halcion<span class="Sup">®</span> (triazolam)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimycobacterial agents</td>
<td class="Rrule" align="left">Rifampin</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Neuroleptics</td>
<td class="Rrule" align="left">ORAP<span class="Sup">®</span> (Pimozide)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">HMG-CoA Reductase Inhibitors </td>
<td class="Rrule" align="left">MEVACOR<span class="Sup">®</span> ALTOPREV<span class="Sup">®</span>, ADVICOR<span class="Sup">®</span> (lovastatin), ZOCOR<span class="Sup">®</span>, VYTORIN<span class="Sup">®</span>, SIMCOR<span class="Sup">®</span> (simvastatin)</td>
</tr>
</tbody>
</table>
<p>INVIRASE causes increased blood levels of some of these compounds. This can lead to serious or life-threatening reactions such as irregular heartbeat or prolonged sedation.</p>
<p><span class="Bold">The following medicines may increase blood levels and side effects of INVIRASE when taken with INVIRASE/NORVIR:</span></p>
<ul>
<li>REYATAZ<span class="Sup">®</span> (atazanavir, used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>)</li>
<li>PRILOSEC<span class="Sup">®</span> (omeprazole, for treatment of gastrointestinal conditions such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> or <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</li>
<li>BIAXIN<span class="Sup">®</span> (clarithromycin, for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)</li>
<li>CRIXIVAN<span class="Sup">®</span> (indinavir, used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>)</li>
</ul>
<p><span class="Bold">INVIRASE/NORVIR may not work as well when taken together with the following medicines, herbal products, or dietary supplements: </span></p>
<ul>
<li>SUSTIVA<span class="Sup">® </span>(efavirenz, used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>)</li>
<li>VIRAMUNE<span class="Sup">®</span> (nevirapine, used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>)</li>
<li>APTIVUS<span class="Sup">®</span> ([tipranavir]/NORVIR [ritonavir] used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>)</li>
<li>Anticonvulsants such as CARBATROL<span class="Sup">®</span> (carbamazepine), phenobarbital, and DILANTIN<span class="Sup">®</span> (phenytoin)</li>
<li>MYCOBUTIN<span class="Sup">®</span> (rifabutin, an antimycobacterial agent)</li>
<li>Corticosteroids such as dexamethasone</li>
<li>Garlic capsules, an herbal product sold as a dietary supplement</li>
<li>St. John's wort (<span class="Italics">Hypericum perforatum</span>) or products containing St. John's wort, an herbal product sold as a dietary supplement</li>
</ul>
<p><span class="Bold">Your healthcare provider may need to monitor your therapy more closely if you take INVIRASE/NORVIR  with the following medicines: </span></p>
<ul>
<li>CIALIS<span class="Sup">®</span> (tadalafil), LEVITRA<span class="Sup">®</span> (vardenafil), or VIAGRA<span class="Sup">®</span> (sildenafil citrate) used for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>. INVIRASE may increase the chances of serious side effects that can happen with CIALIS, LEVITRA, or VIAGRA</li>
<li>COUMADIN<span class="Sup">®</span> (warfarin) (a blood thinner)</li>
<li>Antidepressants such as DESYREL<span class="Sup">®</span> (trazodone), ELAVIL<span class="Sup">®</span> (amitriptyline), or TOFRANIL<span class="Sup">®</span> (imipramine)</li>
<li>Benzodiazepines used as sedatives or sleeping pills such as XANAX<span class="Sup">®</span> (alprazolam), TRANXENE<span class="Sup">®</span> (clorazepate), VALIUM<span class="Sup">®</span> (diazepam), and DALMANE<span class="Sup">®</span> (flurazepam)</li>
<li>LIPITOR<span class="Sup">®</span> (atorvastatin) and CRESTOR<span class="Sup">®</span> (rosuvastatin) used for lowering <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>Calcium channel blockers used for treatment of high blood pressure or heart disease, such as diltiazem (also known as CARDIZEM<span class="Sup">®</span>, CARTIA XT<span class="Sup">®</span>, DILACOR XR<span class="Sup">®</span>, DILTZAC<span class="Sup">®</span> TAZTIA XT<span class="Sup">®</span>, TIAZAC<span class="Sup">®</span>), PLENDIL<span class="Sup">®</span> (felodipine), PROCARDIA<span class="Sup">®</span> (nifedipine), CARDENE<span class="Sup">®</span> (nicardipine), NIMOTOP<span class="Sup">®</span> (nimodipine), verapamil-containing medications (such as CALAN<span class="Sup">®</span>, VERELAN<span class="Sup">®</span>), amlodipine-containing medications (such as CADUET<span class="Sup">®</span>, NORVASC<span class="Sup">®</span>), SULAR<span class="Sup">®</span> (nisoldipine), and DYNACIRC<span class="Sup">®</span> (isradipine)</li>
<li>NIZORAL<span class="Sup">®</span> (ketoconazole) and SPORANOX<span class="Sup">®</span> (itraconazole) used to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></li>
<li>Medicines to prevent organ <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>: SANDIMMUNE<span class="Sup">® </span>(cyclosporine), NEORAL<span class="Sup">®</span> (cyclosporine), RAPAMUNE<span class="Sup">®</span> (sirolimus), or PROGRAF<span class="Sup">®</span> (tacrolimus)</li>
<li>FLONASE<span class="Sup">®</span>, FLOVENT<span class="Sup">®</span>, ADVAIR<span class="Sup">®</span> (fluticasone propionate), given by nose or inhaled to treat allergic symptoms or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li>LANOXIN<span class="Sup">®</span> (digoxin) used to treat heart rhythm problems or other heart conditions</li>
<li>Oral contraceptives containing ethinyl estradiol used for preventing pregnancy</li>
<li>Methadone used for the treatment of opioid addiction</li>
</ul>
<p><span class="Bold">Does INVIRASE cure HIV/AIDS?</span></p>
<p>INVIRASE does not cure AIDS, and it does not prevent you from getting other illnesses that result from advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. In addition, INVIRASE has not been shown to reduce the risk that you may transmit HIV to others through sexual contact or infected blood. You must continue to follow all of your doctor's recommendations for managing your illness.</p>
<p><span class="Bold">What else should I discuss with my doctor?</span></p>
<p>Inform your doctor:</p>
<ul>
<li>If you are pregnant or become pregnant while taking INVIRASE. The effects of INVIRASE on pregnant women or unborn babies are not yet fully known. In addition, experts advise against breast-feeding if you are HIV positive, to reduce the risk of passing the virus to your baby.</li>
<li>If you are taking anti-HIV medications. Your doctor may want to change one or more of your anti-HIV drugs in order to achieve the best results when you start treatment with INVIRASE.</li>
<li>If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or if you have <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or other liver disease, your doctor should decide if INVIRASE is right for you.</li>
<li>If you have ever taken FORTOVASE, discuss with your doctor whether INVIRASE is right for you.</li>
</ul>
<p><span class="Bold">How is INVIRASE supplied?</span></p>
<p>INVIRASE is available as light brown and green capsules in a 200-mg strength. INVIRASE comes in bottles of 270 capsules.</p>
<p>INVIRASE is also available as light orange to greyish- or brownish-orange tablets in a 500-mg strength. INVIRASE comes in bottles of 120 tablets.</p>
<p><span class="Bold">How should I store INVIRASE?</span></p>
<p>INVIRASE capsules and tablets should be stored at room temperature. The bottles should be kept tightly closed.</p>
<p>INVIRASE has been prescribed specifically for you, and only for a particular condition. Do not use it for anything else. Do not give it to anyone else. If you think you have taken more than your prescribed dose, seek medical attention.</p>
<p><span class="Bold">Keep this medication and all other medications out of the reach of children.</span> Do not keep medicine that is out of date or that you no longer need. Be sure that if you throw any medicine away, it is out of the reach of children.</p>
<p>This provides only a brief summary of product information about INVIRASE. If you have any questions about INVIRASE or HIV, talk to your doctor.</p>
<p>The brands listed are trademarks of their respective owners and are not trademarks of Roche Laboratories, Inc. The makers of these brands are not affiliated with and do not endorse Roche Laboratories, Inc. or its products.</p>
<p><span class="Italics">If you have any questions about INVIRASE, call toll free at 1-800-910-4687.</span></p>
<p>Distributed by:<br><span class="Bold">Roche Pharmaceuticals</span><br>Roche Laboratories Inc.<br>340 Kingsland Street<br>Nutley, New Jersey 07110-1199</p>
<p>Copyright © 1999-2010 by Roche Laboratories Inc. All rights reserved.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
<p>Representative sample of labeling (see the <a href="#HS">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Tablets Bottle</h1>
<p class="First">NDC 53808-0674-1</p>
<p><span class="Bold">Invirase<span class="Sup">®</span></span><br>(saquinavir mesylate) Tablets 						</p>
<p><span class="Bold">500 mg</span></p>
<p>Each tablet contains<br>saquinavir mesylate equivalent to<br>500 mg saquinavir (free base).</p>
<p><span class="Bold">30 tablets<br>Rx only</span></p>
<p><span class="Bold">ALERT: Find out about medicines that<br>should NOT be taken with INVIRASE.</span></p>
<p><span class="Bold">Roche</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 500 mg Tablets Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8b53129-06ab-4143-b9b7-7675e49a52ef&amp;name=Invirase500mg(Roche).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INVIRASE 		
					</strong><br><span class="contentTableReg">saquinavir mesylate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0674(NDC:0004-0244)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SAQUINAVIR MESYLATE</strong> (saquinavir) </td>
<td class="formItem">SAQUINAVIR MESYLATE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (light orange to greyish-or brownish-orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ROCHE;SQV;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0674-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021785</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e981c067-b7f7-440b-a4d3-1cd79038af4a</div>
<div>Set id: b8b53129-06ab-4143-b9b7-7675e49a52ef</div>
<div>Version: 3</div>
<div>Effective Time: 20100920</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
